Perceptive Advisors’s BioCryst Pharmaceuticals BCRX Stock Holding History

Perceptive Advisors’s Portfolio BCRX Stock Details BCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$103M	Buy	10,308,888 +2,874,855	+39%	+$26M	1.55%	23
2026 Q1	$70.8M	Buy	7,434,033 +4,271,504	+135%	+$33.2M	1.38%	21
2025 Q4	$24.7M	Buy	+3,162,529	New	+$22.9M	0.44%	55
2017 Q1	–	Sell	-1,330,240	Closed	-$8.42M	–	167
2016 Q4	$8.42M	Buy	+1,330,240	New	+$6.92M	0.6%	41
2015 Q4	–	Sell	-123,745	Closed	-$1.41M	–	158
2015 Q3	$1.41M	Sell	123,745 -346,255	-74%	-$4.62M	0.11%	90
2015 Q2	$7.02M	Buy	+470,000	New	+$5.34M	0.42%	51
2014 Q1	–	Sell	-197,500	Closed	-$1.5M	–	130
2013 Q4	$1.5M	Buy	197,500 +6,912	+4%	+$43.8K	0.18%	59
2013 Q3	$1.39M	Buy	+190,588	New	+$967K	0.11%	66

Other funds holding BCRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

TCM

TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

Jupiter Topco New York $245B AUM

VPC

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Perceptive Advisors's BCRX Position: Q2 2026 in Review

Perceptive Advisors increased its BioCryst Pharmaceuticals (BCRX) stake by 39% in Q2 2026, buying an estimated $26M and bringing the position to 10,308,888 shares worth $103M. The position accounts for 1.55% of the portfolio, ranked #23.

Perceptive Advisors first reported a position in BCRX in Q3 2013 and has held it in 8 quarters since. 318 funds tracked by Wall St. Rank hold BCRX as of Q2 2026.

Perceptive Advisors held 10,308,888 shares of BioCryst Pharmaceuticals worth $103M as of Q2 2026.
Perceptive Advisors bought 2,874,855 BioCryst Pharmaceuticals shares in Q2 2026, an estimated $26M.
BioCryst Pharmaceuticals made up 1.55% of Perceptive Advisors's portfolio in Q2 2026, its #23 holding.
Perceptive Advisors first reported a position in BioCryst Pharmaceuticals in Q3 2013 and has held it in 8 quarters since.
318 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q2 2026.

Based on Perceptive Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.